DBV Technologies S.A. (DBV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DBV Technologies S.A. (DBV) has a cash flow conversion efficiency ratio of -0.614x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-32.44 Million ≈ $-37.92 Million USD) by net assets (€52.85 Million ≈ $61.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DBV Technologies S.A. - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how DBV Technologies S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DBV current and long-term liabilities for a breakdown of total debt and financial obligations.
DBV Technologies S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Diplomat Holdings Ltd
TA:DIPL
|
0.049x |
|
Poongsan Holdi
KO:005810
|
0.011x |
|
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
|
-0.245x |
|
Zhejiang Wanfeng Chemical Co. Ltd. A
SHG:603172
|
N/A |
|
Advanced Enzyme Technologies Limited
NSE:ADVENZYMES
|
0.042x |
|
Suzhou Harmontronics Auto Tech Co Ltd
SHG:688022
|
-0.032x |
|
The York Water Company
NASDAQ:YORW
|
0.033x |
|
Concord Securities Co Ltd
TWO:6016
|
0.234x |
Annual Cash Flow Conversion Efficiency for DBV Technologies S.A. (2011–2024)
The table below shows the annual cash flow conversion efficiency of DBV Technologies S.A. from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see DBV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €27.39 Million ≈ $32.02 Million |
€-104.47 Million ≈ $-122.14 Million |
-3.815x | -571.38% |
| 2023-12-31 | €140.19 Million ≈ $163.89 Million |
€-79.65 Million ≈ $-93.12 Million |
-0.568x | -98.41% |
| 2022-12-31 | €194.50 Million ≈ $227.39 Million |
€-55.70 Million ≈ $-65.12 Million |
-0.286x | +73.74% |
| 2021-12-31 | €99.27 Million ≈ $116.06 Million |
€-108.24 Million ≈ $-126.55 Million |
-1.090x | -65.92% |
| 2020-12-31 | €252.01 Million ≈ $294.62 Million |
€-165.61 Million ≈ $-193.61 Million |
-0.657x | +12.28% |
| 2019-12-31 | €218.05 Million ≈ $254.92 Million |
€-163.34 Million ≈ $-190.96 Million |
-0.749x | +33.50% |
| 2018-12-31 | €165.78 Million ≈ $193.81 Million |
€-186.74 Million ≈ $-218.32 Million |
-1.126x | -28.02% |
| 2017-12-31 | €182.88 Million ≈ $213.81 Million |
€-160.91 Million ≈ $-188.12 Million |
-0.880x | -258.89% |
| 2016-12-31 | €267.90 Million ≈ $313.21 Million |
€-65.68 Million ≈ $-76.79 Million |
-0.245x | -195.04% |
| 2015-12-31 | €384.24 Million ≈ $449.21 Million |
€-31.93 Million ≈ $-37.33 Million |
-0.083x | +53.34% |
| 2014-12-31 | €182.22 Million ≈ $213.04 Million |
€-32.45 Million ≈ $-37.94 Million |
-0.178x | +45.72% |
| 2013-12-31 | €74.09 Million ≈ $86.61 Million |
€-24.31 Million ≈ $-28.42 Million |
-0.328x | -23.20% |
| 2012-12-31 | €66.84 Million ≈ $78.15 Million |
€-17.80 Million ≈ $-20.81 Million |
-0.266x | +49.14% |
| 2011-12-31 | €19.79 Million ≈ $23.13 Million |
€-10.36 Million ≈ $-12.11 Million |
-0.524x | -- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of i… Read more